What the FY2027 request buys
Verbatim from the R-2A exhibit for project MT3 of PE 0603384BP. This is the budget justification's own description of work that has not happened yet — the one thing no other level of the budget carries.
- Execute efficacy testing across diverse pathogens and chemical exposures to address respiratory distress, neurocognitive impairment, and vascular dysfunction. - Perform immune modulation effectiveness studies to reduce symptoms induced by viral pathogens. - Validation of efficacy and safety platforms for human-directed therapies to evaluate unintended effects and enable robust risk/benefit determinations. - Advance at least two investigational new drug candidates with supporting biodefense data into later-stage development. - Continue development of comprehensive searchable repository for repurposed pharmaceutical candidates. - Continue development of well-defined testing models for therapeutic candidate evaluation. - Continue anti-viral layered medical defense concept to broaden countermeasure protection.
Decrease due to completion of FY 2026 clinical trials and divestments in toxin countermeasures.
FY2025–FY2026: what came before
Prior-year accomplishments and current-year plans from the same exhibit. Context for the FY2027 plan, not a series — an activity partitions its project exactly in the request year, but can under-cover it in earlier years.
- Continue to execute proof of concept efficacy studies for layered medical defense. - Continue to execute efficacy studies for down-selected lead drug candidates. - Continue development of well-characterized models for testing of advanced therapeutic candidates. - Complete studies to transition one broad spectrum therapeutic candidate to the Agent Directed Therapeutic Program. - Complete studies to transition one host-directed therapeutic candidate to the Host Directed Therapeutic Program. - Execute studies to transition broad spectrum antimicrobial data package to the Rapid Acquisition and Investigation of Drugs for Repurposing Program.
- Transitioned 2 broad-spectrum, agent-directed therapies from early research into advanced development phases. - Progressed development of non-ionic surfactant vesicles and nanolipid particles as platform delivery technologies to minimize dosing requirements and mitigate adverse side-effects. - Continued development of 3 leading host-directed therapeutic candidates for alleviation of respiratory distress resulting from viral infection. - Continued characterization of alternative testing models to facilitate advanced development of broad-spectrum antivirals through FDA regulatory approval.
Three years, and no five-year plan
An R-2A activity publishes the prior year, the current year and the budget year. The FYDP outyears exist at project and program-element level and are deliberately absent here rather than inferred. Estimate types are colored and never summed into one figure.
| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 21.1 |
| FY2026 | Enacted | 22.9 |
| FY2027 | Request | 18.2 |
This activity is 31% of project MT3's FY2027 request and 5.9% of PE 0603384BP's. In the request year the activities under a project sum to it exactly; in the current year they under-cover it in about 9% of cases, so an activity's delta can legitimately exceed its parent's and the two must not be compared row to row.
13 activities in project MT3
Every R-2A line of this project, largest FY2027 request first. Linked where the activity has enough of its own narrative to carry a page; the rest are shown in full on the project page.